⚠ Evidence note: Most trends in this area rest on anecdote and mechanism; where real evidence exists it is usually for narrower claims than the trend makes.
Regenerative Joint Injectables (PRP/ACS/MSC)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-21 — Can Obesity Pharmacotherapy Modify Osteoarthritis? Interpreting Pain Relief, Weight-Loss Quality, and Structural Outcomes.: cross-connection with aoms-for-longevity: AOMs relieve OA pain through load reduction but are explicitly non-disease-modifying, leaving regenerative injectables as the candidate class still being tested for structural joint modification. (novelty: 3)
- 2026-08-10 — Preserving joint healthspan in knee osteoarthritis: a geroscience-guided review of non-surgical therapies and genicular artery embolization.: Geroscience review classifies PRP/ACS/MSC injectables alongside pharmacologic options as primarily symptom-modulating, with lifestyle interventions (weight loss, exercise, education) ranked as the core healthspan levers. [expert-opinion] (novelty: 3)
Open questions
Related
Contributing findings
Preserving joint healthspan in knee osteoarthritis: a geroscience-guided review of non-surgical therapies and genicular artery embolization.
10-aug-2026
novelty 3
per-area 3
strengthens
Novel therapeutic strategies for osteoarthritis: from mechanistic insights to precision medicine.
11-jun-2026
novelty 2
per-area 2
strengthens